Revvity Imipramine Hydrochloride, -, 250uCi (9.25MBq)

Revvity Imipramine (Tofranil) is an anticholinergic tricyclic antidepressant (TCA), and acts as an antagonist at muscarinic acetylcholine receptors. It also has been shown to inhibit serotonin reuptake, norepinephrine reuptake, and to block dopamine D2 receptors. We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, PerkinElmer has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. References for NET576: Steven M. Paul, Moshe Rehavi, Kenner C. Rice, Yitzhak Ittah, Phil Skolnick, Does high affinity [3H] imipramine binding label serotonin reuptake sites in brain and platelet, In Life Sciences, Volume 28, Issue 24, 1981, Pages 2753-2760. Rita Raisman, Michael S. Briley, Salomon Z. Langer, Specific tricyclic antidepressant binding sites in rat brain characterised by high-affinity 3H-imipramine binding, In European Journal of Pharmacology, Volume 61, Issue 4, 1980, Pages 373-380. - PEMSD (Additional S&H or Hazmat Fees May Apply)